Compound ID | 1875

Update compound information

Relebactam

Synonym(s): MK-7655

Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])

Details of activity: DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D beta-lactamases. No intrinsic antibacterial activity
Combined with other compounds: Yes
Description: Synthetic compound. 2019 approved in fixed combination with imipenem/cilastatin (Recarbrio)
Institute where first reported: Merck Sharp & Dohme
Year first mentioned: 2009
Highest developmental phase: Approved by FDA in 2019
Development status: Approved
Chemical structure(s):
Click here for structure editor
Molecular weight: 348.38
Iso. SMILES: C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3
InChI Key: SMOBCLHAZXOKDQ-ZJUUUORDSA-N
Can. SMILES: C1C[C@@H](C(=O)NC2CCNCC2)N3C[C@@H]1N(C3=O)OS(=O)(=O)O
InChI: InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/44129647
Guide to Pharmacology: relebactam
Citation: https://www.sciencedirect.com/science/article/abs/pii/S136952741100110X?via%3Dihub

AntibioticDB is supported by GARDP.

If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.